1-3 of 3
Sophie De Guibert
Close
Sort by
Journal Articles

Impact of diagnostic investigations in the management of CAR T-cell–associated neurotoxicity

Clinical Trials & Observations
Matteo Mauget, Sophie Lemercier, Quentin Quelven, Adel Maamar, Faustine Lhomme, Sophie De Guibert, Roch Houot, Guillaume Manson
Journal: Blood Advances
Blood Adv (2024) 8 (10): 2491–2498.
https://doi.org/10.1182/bloodadvances.2023011669
Published: 2024
Includes: Supplemental data
Journal Articles

A fixed-duration immunochemotherapy approach in CLL: 5.5-year results from the phase 2 ICLL-07 FILO trial

Clinical Trials & Observations
Anne-Sophie Michallet, Rémi Letestu, Magali Le Garff-Tavernier, Lydia Campos, Michel Ticchioni, Marie-Sarah Dilhuydy, Stephane Morisset, Valérie Rouille, Béatrice Mahé, Kamel Laribi, Bruno Villemagne, Emmanuelle Ferrant, Olivier Tournilhac, Alain Delmer, Lysiane Molina, Véronique Leblond, Cécile Tomowiak, Sophie de Guibert, Frederique Orsini-Piocelle, Anne Banos, Philippe Carassou, Guillaume Cartron, Luc Mathieu Fornecker, Loic Ysebaert, Caroline Dartigeas, Margot Truchan-Graczyk, Jean-Pierre Vilque, Thérèse Aurran Schleinitz, Florence Cymbalista, Stéphane Leprêtre, Vincent Lévy, Florence Nguyen-Khac, Pierre Feugier
Journal: Blood Advances
Blood Adv (2023) 7 (15): 3936–3945.
https://doi.org/10.1182/bloodadvances.2022009594
Published: 2023
Includes: Supplemental data
Journal Articles

Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists

Clinical Trials & Observations
Gaëlle Drillet, Faustine Lhomme, Sophie De Guibert, Guillaume Manson, Roch Houot
Journal: Blood Advances
Blood Adv (2023) 7 (4): 537–540.
https://doi.org/10.1182/bloodadvances.2022008066
Published: 2023
Includes: Supplemental data